|Bid||602.72 x 1300|
|Ask||603.71 x 1400|
|Day's Range||592.45 - 608.23|
|52 Week Range||271.37 - 664.64|
|Beta (5Y Monthly)||0.55|
|PE Ratio (TTM)||23.36|
|Earnings Date||Nov 03, 2020 - Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||673.84|
Is (REGN) Outperforming Other Medical Stocks This Year?
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Sanofi and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Biotech Regeneron Pharmaceuticals has a cocktail of antibodies for treating Covid-19. Cannacord analyst John Newman says the treatment is “critical” because a vaccine can’t treat an active disease.